U.S. Unfractionated Heparin Market Exclusivity – Industry will Drive Huge ROI at US$ 501.5 Million during 2019

www.pharmiweb.com
4 min read
difficult
Impact Analysis of Covid-19The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.Request FREE SampleAccording to The U.S. Unfractionated Heparin Market Report, by Source (Porcine and Bovine), by Injection Type (IV Injection and Subcutaneous Injection), and by Disease Indication (Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism & Arterial Embolism), published by Coherent Market Insights, the U.S. unfractionated heparin market was valued at US$ 335.4 million in 2018 and is expected to exhibit a CAGR of 4.5% over the forecast period (2019 – 2027).Increasing prevalence of thromboem...
Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

According to The U.S. Unfractionated Heparin Market Report, by Source (Porcine and Bovine), by Injection Type (IV Injection and Subcutaneous Injection), and by Disease Indication (Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism & Arterial Embolism), published by Coherent Market Insights, the U.S. unfractionated heparin market was valued at US$ 335.4 million in 2018 and is expected to exhibit a CAGR of 4.5% over the forecast period (2019 – 2027).

Increasing prevalence of thromboembolic diseases is expected to boost growth of the U.S. unfractionated heparin market over the forecast period. For instance, according to the Circulation Research Journal, a journal of the American Heart Association (AHA), in 2016, in the U.S., age-stratified incidence of venous thromboembolism was 143 per 100,000 among people of age 40 to 49 years, 200 per 100,000 among people of age 50 to 59 years, 391 per 100,000 among people of age 60 to 69 years, 727 per 100,000 among people of age 70 to 79 years, and 1,134 per 100,000 among people of age ≥80 years.

Read Press Release: https://www.coherentmarketinsights.com/press-release/us-unfractionated-heparin-market-2585

Moreover, increasing geriatric population and incidence of obesity is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Moreover, according to the Centers of Disease Control and Prevention, Behavioral Risk Factor Surveillance System, 2018, 71424.3 thousand people in the U.S. suffer from obesity.

Favorable regulatory scenario is expected to offer lucrative growth opportunity for players in the U.S. unfractionated heparin…
CDN Newswire
Read full article